Citation: Cr. Yates et al., PHARMACODYNAMIC MONITORING OF CANCER-CHEMOTHERAPY - CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA AS A MODEL, Therapeutic drug monitoring, 20(5), 1998, pp. 453-458
Authors:
LOENNECHEN T
YATES CR
FESSING MY
RELLING MV
KRYNETSKI EY
EVANS WE
Citation: T. Loennechen et al., ISOLATION OF A HUMAN THIOPURINE S-METHYLTRANSFERASE (TPMT) COMPLEMENTARY-DNA WITH A SINGLE NUCLEOTIDE TRANSITION A719G (TPMT-ASTERISK-3C) AND ITS ASSOCIATION WITH LOSS OF TPMT PROTEIN AND CATALYTIC ACTIVITY INHUMANS, Clinical pharmacology and therapeutics, 64(1), 1998, pp. 46-51
Authors:
KRYNETSKI EY
FESSING MY
YATES CR
SUN DX
SCHUETZ JD
EVANS WE
Citation: Ey. Krynetski et al., PROMOTER AND INTRONIC SEQUENCES OF THE HUMAN THIOPURINE S-METHYLTRANSFERASE (TPMT) GENE ISOLATED FROM A HUMAN PAC1 GENOMIC LIBRARY, Pharmaceutical research, 14(12), 1997, pp. 1672-1678
Authors:
YATES CR
KRYNETSKI EY
LOENNECHEN T
FESSING MY
TAI HL
PUI CH
RELLING MV
EVANS WE
Citation: Cr. Yates et al., MOLECULAR DIAGNOSIS OF THIOPURINE S-METHYLTRANSFERASE DEFICIENCY - GENETIC-BASIS FOR AZATHIOPRINE AND MERCAPTOPURINE INTOLERANCE, Annals of internal medicine, 126(8), 1997, pp. 608
Authors:
KRYNETSKI EY
TAI HL
YATES CR
FESSING MY
LOENNECHEN T
SCHUETZ JD
RELLING MV
EVANS WE
Citation: Ey. Krynetski et al., GENETIC-POLYMORPHISM OF THIOPURINE S-METHYLTRANSFERASE - CLINICAL IMPORTANCE AND MOLECULAR MECHANISMS, Pharmacogenetics, 6(4), 1996, pp. 279-290
Authors:
YATES CR
KRYNETSKI E
TAI HL
LOENNECHEN T
EVANS WE
Citation: Cr. Yates et al., TPMT-ASTERISK-3 IS THE MOST PREVALENT MUTANT ASSOCIATED WITH THIOPURINE S-METHYLTRANSFERASE (TPMT) DEFICIENCY IN CAUCASIANS, Clinical pharmacology and therapeutics, 59(2), 1996, pp. 37-37
Authors:
TAI HL
KRYNETSKI EY
YATES CR
LOENNECHEN T
FESSING MY
KRYNETSKAIA NF
EVANS WE
Citation: Hl. Tai et al., THIOPURINE S-METHYLTRANSFERASE DEFICIENCY - 2 NUCLEOTIDE TRANSITIONS DEFINE THE MOST PREVALENT MUTANT ALLELE ASSOCIATED WITH LOSS OF CATALYTIC ACTIVITY IN CAUCASIANS, American journal of human genetics, 58(4), 1996, pp. 694-702